Page 34 - Read Online

Page 22 of 22 Ballestri et al. Metab Target Organ Damage 2023;3:1 https://dx.doi.org/10.20517/mtod.2022.23

patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. Clin Gastroenterol Hepatol
2021;19:806-815.e5. DOI PubMed
109. Mangla N, Ajmera VH, Caussy C, et al. Liver stiffness severity is associated with increased cardiovascular risk in patients with type 2
diabetes. Clin Gastroenterol Hepatol 2020;18:744-746.e1. DOI PubMed PMC
110. Johnson AL, Hayward KL, Patel P, et al. Predicting liver-related outcomes in people with nonalcoholic fatty liver disease: the
prognostic value of noninvasive fibrosis tests. Hepatol Commun 2022;6:728-39. DOI PubMed PMC
111. Petta S, Wong VW, Cammà C, et al. Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver
fibrosis in patients with NAFLD. Aliment Pharmacol Ther 2017;46:617-27. DOI PubMed
112. Chan WK, Treeprasertsuk S, Goh GB, et al. Optimizing use of nonalcoholic fatty liver disease fibrosis score, fibrosis-4 score, and
liver stiffness measurement to identify patients with advanced fibrosis. Clin Gastroenterol Hepatol 2019;17:2570-2580.e37. DOI
PubMed
113. Ballestri S, Romagnoli D, Nascimbeni F, Francica G, Lonardo A. Role of ultrasound in the diagnosis and treatment of nonalcoholic
fatty liver disease and its complications. Expert Rev Gastroenterol Hepatol 2015;9:603-27. DOI PubMed
114. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease:
a meta-analysis. J Hepatol 2016;65:589-600. DOI PubMed
115. Ballestri S, Mantovani A, Nascimbeni F, Lugari S, Lonardo A. Extra-hepatic manifestations and complications of nonalcoholic fatty
liver disease. Future Med Chem 2019;11:2171-92. DOI PubMed
116. Ballestri S, Tana C, Di Girolamo M, et al. Semi-quantitative ultrasonographic evaluation of NAFLD. Curr Pharm Des 2020;26:3915-
27. DOI PubMed
117. Nascimbeni F, Ballestri S, Machado MV, et al. Clinical relevance of liver histopathology and different histological classifications of
NASH in adults. Expert Rev Gastroenterol Hepatol 2018;12:351-67. DOI PubMed
118. Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J
Hepatol 2018;68:335-52. DOI
119. Tamaki N, Imajo K, Sharpton SR, et al. Two-step strategy, fib-4 followed by magnetic resonance elastography, for detecting
advanced fibrosis in NAFLD. Clin Gastroenterol Hepatol ;2022:S1542-3565(22)00077. DOI PubMed
120. Lonardo A, Byrne CD, Targher G. Precision medicine approaches in metabolic disorders and target organ damage: where are we
now, and where are we going? Metab Target Organ Damage 2021. DOI
121. Lonardo A. Renaming NAFLD to MAFLD: could the LDE system assist in this transition? J Clin Med 2021;10:492. DOI PubMed
PMC
122. Lonardo A, Arab JP, Arrese M. Perspectives on precision medicine approaches to nafld diagnosis and management. Adv Ther
2021;38:2130-58. DOI PubMed PMC
123. Lonardo A. Precision medicine in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2022;37:1175-8. DOI PubMed
124. Alkhouri N, Herring R, Kabler H, et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in
patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial. J Hepatol 2022;77:607-18. DOI PubMed
125. Stokman G, van den Hoek AM, Denker Thorbekk D, et al. Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an
engineered eicosapentaenoic acid derivative. Liver Int 2020;40:2860-76. DOI PubMed PMC